In short
This article discusses the ongoing clinical trial of BI 764532, an innovative IgG-like T cell engager that targets DLL3 and CD3. The drug is being studied for its potential in treating relapsed or refractory small cell lung cancer (SCLC) and other neuroendocrine carcinomas. The DAREON™-5 trial aims to evaluate the safety and efficacy of this promising therapy in patients who have progressed after standard treatments.
At a glance
- Drug Name
- BI 764532
- Drug Type
- IgG-like T cell engager binding to DLL3 and CD3
- Trial Name
- DAREON™-5
- Trial Phase
- Phase II
- Target Conditions
- Relapsed/refractory small cell lung cancer, other neuroendocrine carcinomas
- Primary Objectives
- Evaluate safety and efficacy of two dose levels
- Administration
- Intravenous infusion
- Treatment Duration
- 21-day cycles until disease progression or other termination reason
- Key Eligibility
- Adults ≥18 years, confirmed SCLC or neuroendocrine carcinoma, prior platinum-based therapy
- Primary Endpoints
- Objective response rate, treatment-emergent adverse events
What is IGG-Like T Cell Engager Binding to DLL3 and CD3?
IGG-Like T Cell Engager Binding to DLL3 and CD3, also known as BI 764532, is a new experimental drug being studied for the treatment of certain types of cancer. This medication is classified as a T cell engager, which is a type of immunotherapy that helps your body's immune system fight cancer cells.
Target Conditions
BI 764532 is being investigated for the treatment of several types of cancer, including:
- Small Cell Lung Cancer (SCLC): A fast-growing type of lung cancer that usually spreads quickly.
- Extra-pulmonary Neuroendocrine Carcinoma (epNEC): A rare type of cancer that starts in neuroendocrine cells outside the lungs.
- Large Cell Neuroendocrine Carcinoma (LCNEC) of the lung: A rare and aggressive type of lung cancer.
These cancers are part of a group called neuroendocrine carcinomas, which are tumors that form from cells that release hormones into the blood in response to signals from the nervous system.
How the Drug Works
BI 764532 is designed to work in a unique way:
- It targets a protein called DLL3 (Delta-like ligand 3), which is found on the surface of certain cancer cells.
- It also binds to CD3, a protein found on T cells (a type of immune cell that fights infections and cancer).
- By binding to both DLL3 and CD3, the drug acts like a bridge, bringing cancer cells and T cells close together.
- This closeness allows the T cells to recognize and attack the cancer cells more effectively.
This approach is called T cell engagement, and it's a promising new strategy in cancer treatment.
Clinical Trial Details
The drug is currently being studied in a clinical trial called DAREON™-5. Here are some key details about the trial:
- It's a Phase II trial, which means it's testing how well the drug works and checking its safety in a larger group of patients.
- The trial is open-label, meaning both doctors and patients know which treatment is being given.
- It's testing different doses of BI 764532 to find out which one works best.
- The drug is given through an intravenous infusion, which means it's delivered directly into the bloodstream through a vein.
Eligibility Criteria
To participate in this trial, patients must meet certain criteria. Some key points include:
- Patients must be 18 years or older.
- They must have one of the cancers mentioned earlier (SCLC, epNEC, or LCNEC of the lung).
- For SCLC patients, the cancer must have returned or gotten worse after at least two previous treatments, including one with platinum-based chemotherapy.
- For epNEC or LCNEC patients, the cancer must have returned or gotten worse after at least one platinum-based chemotherapy treatment.
- Patients must be in relatively good overall health, with an ECOG score (a measure of a person's ability to perform daily activities) of 0 or 1.
There are also several conditions that would prevent a person from participating in the trial, such as certain other cancers, active infections, or specific medical conditions.
Potential Benefits
While it's important to remember that BI 764532 is still experimental, researchers hope it might offer several benefits:
- It may help shrink tumors or slow their growth in patients whose cancer has returned or gotten worse after other treatments.
- It might provide a new treatment option for patients with limited choices.
- The trial is also looking at how the drug affects patients' quality of life, including their ability to perform daily activities.
Safety Considerations
As with any new treatment, safety is a top priority. The trial is closely monitoring for side effects, including:
- Treatment-emergent adverse events (TEAEs): These are any new medical problems or worsening of existing problems that occur during treatment.
- Immune-related side effects: Since the drug works with the immune system, it could potentially cause the immune system to attack healthy cells.
- Infusion-related reactions: These are side effects that can occur during or shortly after receiving the drug through IV.
Patients in the trial will be closely monitored for these and other potential side effects. It's important to note that the full range of possible side effects may not be known yet, as this is still an experimental treatment.